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ABSTRACT
Although non-medullary thyroid cancer (NMTC) generally has a good prognosis, 30–40% of patients with
distant metastases develop resistance to radioactive iodine (RAI) therapy due to tumor dedifferentiation.
For these patients, treatment options are limited and prognosis is poor. In the present study, expression
and activity of autophagy was assessed in large sets of normal, benign and malignant tissues and was
correlated with pathology, SLC5A5/hNIS (solute carrier family 5 member 5) protein expression, and with
clinical response to RAI ablation therapy in NMTC patients. Fluorescent immunostaining for the autophagy
marker LC3 was performed on 100 benign and 80 malignant thyroid tissues. Semiquantitative scoring was
generated for both diffuse LC3-I intensity and number of LC3-II-positive puncta and was correlated with
SLC5A5 protein expression and clinical parameters. Degree of diffuse LC3-I intensity and number of LC3-II-
positive puncta scoring were not discriminative for benign vs. malignant thyroid lesions. Interestingly,
however, in NMTC patients signiﬁcant associations were observed between diffuse LC3-I intensity and
LC3-II-positive puncta scoring on the one hand and clinical response to RAI therapy on the other hand
(odds ratio [OR] D 3.13, 95% conﬁdence interval [CI] D1.91–5.12, P D 0.01; OR D 5.68, 95%CI D 3.02–10.05,
P D 0.002, respectively). Mechanistically, the number of LC3-II-positive puncta correlated with
membranous SLC5A5 expression (OR D 7.71, 95%CI D 4.15–11.75, P<0.001), number of RAI treatments
required to reach remission (P D 0.014), cumulative RAI dose (P D 0.026) and with overall remission and
recurrence rates (P D 0.031). In conclusion, autophagy activity strongly correlates with clinical response of
NMTC patients to RAI therapy, potentially by its capacity to maintain tumor cell differentiation and to






Patients diagnosed with non-medullary thyroid cancer
(NMTC) are, in addition to determination of the histologi-
cal subtype, regularly classiﬁed according to the differentia-
tion status of the tumor, ranging from well-differentiated to
severely dedifferentiated NMTC.1,2 The ﬁrst-line therapeutic
regimen consists of thyroidectomy followed by ablation of
thyroid (tumor) remnants by 131I radioactive iodine therapy
(RAI). Importantly, in about 30–40% of patients with meta-
static disease this treatment strategy is not curative because
of tumor cell resistance to RAI caused by a process of dedif-
ferentiation and concomitant loss of thyroid-speciﬁc gene
expression including the gene encoding the human sodium
iodide symporter (SLC5A5), leaving patients at high risk of
recurrent or persistent disease.3,4 The current tumor
classiﬁcations do not allow for the identiﬁcation of those
patients that bear RAI refractory tumors and are, hence,
hardly predictive for therapeutic success. Therefore, identiﬁ-
cation of prognostic markers with high predictive value is
warranted in order to reliably estimate RAI treatment
response and to optimize the therapeutic strategy for the
individual patient. Furthermore, identiﬁcation of these
markers and understanding of the mechanisms involved in
the dedifferentiation process could potentially facilitate the
development of novel therapeutic approaches to improve
the clinical response to RAI therapy.
One of the biological processes importantly involved in can-
cer development and progression is autophagy. Autophagy is a
cellular machinery directing cellular metabolism and cell fate.
Autophagy is activated in cells in case of nutrient deprivation,
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hypoxia and DNA damage to facilitate degradation of cyto-
plasmic components (e.g., damaged organelles and misfolded
proteins), which are engulfed into autophagosomes and
degraded following fusion of the autophagosomes with lyso-
somes to form autolysosomes.5 Recycling of degraded cellular
components from autolysosomes provides a source of amino
acids, nucleotides and lipids for adenosine triphosphate pro-
duction and macromolecular synthesis. Autophagy has
emerged as a key player in carcinogenesis and anticancer ther-
apy resistance, including NMTC.6,7 In many tumor types,
autophagy exhibits both promoting and inhibitory effects on
tumor cell survival; on the one hand, autophagy inhibits tumor
growth by inducing tumor cell cycle arrest, whereas, on the
other hand, it is activated as a potent cell survival pathway pro-
moting resistance to anticancer therapies.8-10
We and others have demonstrated in genetic and fundamen-
tal studies that autophagy itself and pathways that directly
inﬂuence autophagy are involved in NMTC and its treatment
response to RAI therapy.11-13 Of interest, also in other cancer
types a clear association between autophagy activity, tumor
aggressiveness and patient outcome has been demon-
strated.14,15 However, no studies have been performed on the
relationship between markers of autophagy with malignant
transformation of thyroid follicular cells and sensitivity to RAI
therapy in a large cohort of NMTC patients.
Punctate and diffuse cytoplasmic staining of LC3 (micro-
tubule-associated protein 1 light chain 3; Atg8 in yeast) is
well established as a marker for autophagy. LC3 is a consti-
tutively expressed protein involved in autophagosome assem-
bly.16-18 Depending on the degree of autophagy activity, LC3
proteins have different subcellular localizations. In the case
of low autophagy activity, most of LC3 is diffusely present in
the cytoplasm, designated as LC3-I. During active autophagy,
however, cytoplasmic LC3-I is conjugated to phosphatidyl-
ethanolamine and incorporated into the lipid membrane of
phagophores, the precursor to autophagosomes, as LC3-II.
Consequently, LC3-II is localized to the cytosolic and lumi-
nal surfaces of mature, double-membraned autophagic
vesicles that microscopically appear as intracellular puncta.
At a later stage of the autophagic ﬂux, i.e. fusion of the auto-
phagosome with the lysosome, LC3-II on the autophagosome
cytosolic surface is delipidated to LC3-I and recycled into the
cytosol, whereas luminal LC3-II that was present on the
luminal surface is degraded.19
In the present study, we hypothesized that the degree of
LC3-I expression on the one hand and autophagy activity as
reﬂected by the number of LC3-II-positive puncta on the
other is different in patients with either benign or malignant
thyroid lesions and that it correlates with the therapeutic
efﬁcacy of RAI treatment in NMTC patients. For this,
expression of both unconjugated LC3-I and conjugated
LC3-II has been assessed on tissue sections derived from
benign thyroid tissues (Graves, goiter, follicular adenoma)
and thyroid malignancies (papillary, follicular and anaplastic
NMTC) and was compared to normal thyroid tissue. More-
over, the extent of autophagy expression and activity has
been examined in dedifferentiated and RAI refractory non-
medullary thyroid tumors vs. tumors that were well differen-
tiated and exhibited RAI avidity.
Results
Validation of LC3 immunoﬂuorescent staining with
transmission electron microscopy and LC3 immunoblotting
Transmission electron microscopy is regarded as the gold
standard for visualizing autophagosomes. In order to vali-
date immunoﬂuorescent LC3-II staining for reliable quanti-
ﬁcation of autophagy activity, electron microscopy images
were generated in parallel from fresh material obtained
from 2 PTC patients. Representative pictures are depicted
in Figure 1A, demonstrating concordant LC3-II-positive
puncta scoring generated by both methods in the same tis-
sue specimen. Of note, numerous double-membraned auto-
phagosomes were detected undergoing lysosomal fusion,
conﬁrming active autophagy. Of note, most of the detected
autophagosomes appeared to contain colloid. Additional
validations were performed on the non-medullary thyroid
cancer cell line TPC-1 that was treated with either vehicle
or with 10 mM 3-methyladenine (3-MA, an autophagy
inhibitor), which demonstrated corresponding changes in
LC3-II-positive puncta and left LC3-I intensity unaffected
(Fig. 1B). These results were conﬁrmed by LC3 immuno-
blotting (Fig. 1C).
Comparison of diffuse LC3-I intensity and number of
LC3-II-positive puncta scores across different tissue
subgroups and comparison with SQSTM1 expression
To compare the obtained semiquantitative scores for diffuse
LC3-I staining intensity with the observed number of LC3-II-
positive puncta within and across different tissue subgroups
representing either normal, benign or malignant thyroid tissue,
cross-tabulations were generated (Fig. 2A). These comparisons
indicate that elevated expression of LC3-I was not necessarily
coexistent with a high number of LC3-II-positive puncta, as
exempliﬁed in Fig. 2B; in the patient tissue depicted in the left
panel, intermediate LC3-I intensity and a high number of
LC3-II-positive puncta could be observed. In contrast, in the
right panel, LC3-I intensity was high although LC3-II-positive
puncta were nearly absent, scored as “0: none,” indicating mini-
mal autophagy activity. LC3-I expression and incorporation of
LC3-II into phagophores are therefore distinctly regulated pro-
cesses, as reported previously.20,21 To assess whether the degree
of LC3-II staining was related to SQSTM1 expression, 10 of the
analyzed NMTC specimens were stained for both markers. No
signiﬁcant correlations were observed (Fig. 2C).
Association of diffuse LC3-I intensity and LC3-II-positive
puncta with thyroid pathology
In order to examine the role of autophagy expression and activity
in benign versus malignant thyroid pathology, the degree of dif-
fuse LC3-I intensity and the number of LC3-II-positive puncta
was assessed in both benign (normal thyroid tissue, Graves dis-
ease, goiter, follicular adenoma) and malignant lesions (PTC,
FTC, FVPTC, ATC). After the assessment of autophagy scores,
the distribution of these scores was analyzed in all subgroups of
either benign or malignant thyroid lesions. The results indicate
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that neither autophagy expression (i.e., degree of diffuse LC3-I
intensity) nor activity scores (i.e., number of LC3-II-positive
puncta) were discriminative for benign vs. malignant tissues,
meaning that this pathological dichotomy was not reproduced by
the degree of either diffuse LC3-I intensity or LC3-II-positive
puncta (Fig. 3). Moreover, the distribution of autophagy scores
was similar in all analyzed subgroups, with the exception of the
small group of ATC patients, and no statistically signiﬁcant differ-
ences could be demonstrated between any combinations of 2 ran-
domly chosen subgroups (data not shown).
Association of diffuse LC3-I intensity and LC3-II-positive
puncta with RAI uptake
Within the group of differentiated NMTC tissues compris-
ing tumor and normal thyroid material obtained from PTC,
FTC and FVPTC patients, data have been gathered on the
extent of RAI uptake and the success rate of RAI ablation
therapy in the corresponding tumors and surrounding nor-
mal thyroid tissue. Strikingly, both diffuse LC3-I intensity
(P D 0.01, OR D 3.13 [95%CI 1.91–5.12]) and the number
of LC3-II-positive puncta (P D 0.002, OR D 5.68 [95%CI
3.02–10.05]) were associated with clinical response to RAI
(Fig. 4A, B). Speciﬁcally, tumors that had a poor response
to RAI also displayed low LC3-I expression and a strongly
reduced number of LC3-II-conjugated autophagosomes.
Conversely, tumors characterized by high RAI uptake har-
bored signiﬁcantly higher LC3-I expression and elevated
numbers of LC3-II-positive puncta. No such associations
were apparent in normal thyroid tissues surrounding
NMTC tumors, suggesting a distinctive role for autophagy
in maintaining expression of differentiation markers in thy-
roid malignancies as compared to physiological thyroid fol-
licular cells (Fig. 4C, D).
Figure 1. Validation of immunoﬂuorescent LC3 staining and comparison of diffuse LC3-I intensity with LC3-II-positive puncta scores. (A) Comparison of autophagosome
detection by transmission electron microscopy (left and middle panels) or by LC3 immunoﬂuorescent staining (right panel). Arrows indicate autophagosomes alone, dou-
ble arrows indicate colocalization of autophagosomes with lysosomes. N, nucleus. (B) LC3-I intensity and LC3-II-positive puncta scoring of TPC-1 cells treated with vehicle
or 3-methyladenine (3-MA, 10 mM) for 4 h. Data have been generated by quantitative analysis with FIJI software. P-values have been calculated by the Mann-Whitney
U test. (C) LC3 western blot of TPC-1 cells treated with dimethyl sulfoxide vehicle or 3-methyladenine for 4 h. GAPDH staining was performed to serve as loading control.
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Figure 2. Distribution of LC3 scoring in normal, benign and malignant tissue groups and its correlation with SQSTM1 expression. (A) Cross-tabulations of diffuse LC3-I
intensity and LC3-II-positive puncta scores within the normal, benign and malignant tissue groups. Intermed., Intermediate. (B) Examples of LC3 staining patterns and
autophagy scoring in tissue samples of 2 non-medullary thyroid cancer patients (1000x magniﬁcation). (C) Correlation between number of LC3-II-positive puncta with
SQSTM1 expression in non-medullary thyroid cancer tissue specimens (N D 10).
Figure 3. Distribution of diffuse LC3-I intensity (A) and LC3-II-positive puncta (B) scores divided by tissue group (normal and benign versus malignant) and subdivided by
thyroid pathology. P-values were generated by x2 tests. FA, follicular adenoma; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; FVPTC, follicular-variant papil-
lary thyroid cancer; ATC, anaplastic thyroid cancer.
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Association of iodide uptake, LC3-I expression and LC3-II
positive puncta with membranous SLC5A5 expression
Given the differential capacity in iodide uptake between
tumors with either high or low autophagy activity, we hypoth-
esize that a relationship could exist between SLC5A5 expres-
sion on the cell surface of thyroid tumor cells and autophagy.
To examine this possibility, data on membranous SLC5A5
expression that were obtained for the same tissue specimens
in a previous study22 and its potential association with LC3-I
expression and number of LC3-II-positive puncta were ana-
lyzed. First, the degree of membranous SLC5A5 expression
was correlated with the RAI uptake capacity and clinical
response to RAI of the investigated tumors, which demon-
strated that the presence of membranous SLC5A5 expression
strongly predicted the clinical response to RAI therapy, as
expected (P < 0.001, OR D 9.15 [95%CI 6.43–13.56]). Next, it
was analyzed whether autophagy was related to membranous
SLC5A5 expression. Indeed, membranous SLC5A5 expression
was diminished in tumors with low autophagy activity
whereas in tumors with membranous SLC5A5 expression,
activity of the autophagy machinery, i.e., high numbers of
LC3-II-positive puncta, was strongly elevated (P<0.001, OR D
7.71 [95%CI 4.15–11.75]). Interestingly, this association was
not observed between membranous SLC5A5 expression and
intensity scores of diffuse LC3-I expression (P D 0.22), sug-
gesting a less important role for unconjugated LC3-I as com-
pared to phagophore/autophagosome-associated LC3-II in
maintaining a differentiated state of NMTC (Fig. 5).
Association of autophagy scoring with clinical
characteristics
To assess whether autophagy expression and activity are
related to patient characteristics and outcome of the disease,
autophagy scores were correlated with clinical parameters
including tumor-node-metastasis (TNM) staging, cumulative
RAI dose required to reach remission and disease persistence
and recurrence rates. Whereas no signiﬁcant associations
were observed between clinical parameters and unconjugated
LC3-I (Table 1), the number of LC3-II-positive puncta was
clearly elevated in patients with low cumulative RAI dose,
high remission rates and low recurrence rates during
follow-up (Table 2).
Discussion
In the present study, we demonstrated the relation between
active autophagy and clinical response to RAI therapy in
NMTC patients. High autophagy activity, as reﬂected by high
numbers of LC3-II-positive puncta in the cytoplasm of thyroid
tumor cells, was correlated in a proportional fashion with
uptake of and clinical response to RAI and with higher remis-
sion rates, less tumor recurrences and less exposure to RAI
therapy, at least in part by its association with functional
SLC5A5 expression on the basal membrane of thyroid tumor
cells. Consequently, in case of high autophagy activity, the
iodide uptake machinery was mostly intact, facilitating proﬁ-
cient 131I accumulation that allowed for complete eradication
Figure 4. Distribution of diffuse LC3-I intensity and LC3-II positive puncta scores within the malignant thyroid tissue group (A, B; N D 77) and adjacent normal thyroid tis-
sue (C, D; N D 77) and its correlation with uptake of and clinical response to radioactive iodine treatment in the corresponding non-medullary thyroid carcinoma patients.
P-values were generated by x2 tests.
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of malignant thyroid follicular cells in tumor remnants and
metastases present after thyroidectomy.
RAI treatment is part of the standard of care for NMTC
patients and is applied after thyroid surgery in order to eradicate
thyroid (tumor) remnants and small metastases. The major ther-
apeutic challenge in a subset of these patients is the development
of resistance to RAI therapy in malignant cells, leaving these
patients at high risk of tumor recurrence and outgrowth of
metastases. Although the exact cellular mechanisms involved in
conferring RAI therapy resistance remain elusive, it has been
well established that a process of dedifferentiation accompanies
resistance, i.e., there is loss of thyroid-speciﬁc gene expression.3,23
In other tissues and in different contexts, autophagy has been
demonstrated to play a signiﬁcant role in determining cell fate by
directing pathways of proliferation and differentiation.24,25 Our
previous studies have shown that inhibiting the MTOR kinase, a
central player in the pathogenesis of NMTC, leads to restored
SLC5A5 expression and iodide uptake in NMTC cell lines.12 One
of the main downstream effects of MTOR is inhibition of auto-
phagy, meaning that in the case of MTOR inhibition, autophagy
Figure 5. Correlation of membranous SLC5A5 (mSLC5A5) expression with uptake of and clinical response to radioactive iodine treatment (A), with diffuse LC3-I intensity
(B) and with LC3-II-positive puncta scores (C) in non-medullary thyroid carcinoma tissues (N D 77). P-values were generated by x2 tests.
Table 1. Correlation between patient characteristics and category of autophagy expression score in the corresponding NMTC tumor tissues (diffuse LC3-I intensity).
Category autophagy expression (diffuse LC3-I intensity)
Patient characteristics None (N=3) Low (N=28) Intermediate (N=29) High (N=17) P-value
Age at diagnosis in years (mean [§SD ]) 46.9 (§15 .2) 52.2 (§15 .4) 50.2 (§17 .0) 51.9 (§17 .2) 0.832
Gender (Female/Male) 2/1 19/9 20/9 11/6 0.881
T-stage T1 — 1 (3.6%) 2 (6.9%) — 0.277
T2 — 4 (14.3%) 3 (10.3%) 2 (11.8%)
T3 1 (33.3%) 5 (17.9%) 3 (10.3%) 4 (23.5%)
T4 2 (66.7%) 16 (57.1%) 18 (62.1%) 11 (64.7%)
Tx — 2 (7.1%) 3 (10.3%) —
N-stage N0 2 (66.7%) 17 (60.7%) 15 (51.7%) 6 (35.3%) 0.373
N1 1 (33.3%) 7 (25.0%) 11 (37.9%) 8 (47.1%)
Nx — 4 (14.3%) 3 (10.3%) 3 (17.6%)
M-stage M0 3 (100.0%) 17 (60.7%) 22 (75.9%) 10 (58.8%) 0.835
M1 — 8 (28.6%) 5 (17.2%) 5 (29.4%)
Mx — 3 (10.7%) 2 (6.9%) 2 (11.8%)
Nr. RAI treatments 0-1 2 (66.7%) 15 (53.6%) 17 (58.6%) 10 (58.8%) 0.146
2 1 (33.3%) 13 (46.4%) 12 (41.4%) 7 (41.2%)
Cumulative RAI dose <100 mCi — 9 (32.1%) 10 (34.5%) 9 (52.9%) 0.089
100-200 mCi 1 (33.3%) 4 (14.3%) 12 (41.4%) 4 (23.5%)
>200 mCi 2 (66.7%) 15 (53.6%) 7 (24.1%) 4 (23.5%)
Disease after ablation Remission 2 (66.7%) 15 (53.6%) 17 (58.6%) 10 (58.8%) 0.329
Persistent 1 (33.3%) 13 (46.4%) 12 (41.4%) 7 (41.2%)
Disease status during follow-up Remission 2 (66.7%) 17 (60.7%) 12 (41.4%) 11 (64.7%) 0.517
Persistent 1 (33.3%) 10 (35.7%) 16 (55.2%) 6 (35.3%)
Recurrent — 1 (3.6%) 1 (3.4%) —
P-values are generated by comparing group “none C low” with group “intermediateC high."
1200 T. S. PLANTINGA ET AL.
becomes active and could therefore be responsible for the observed
redifferentiation in these cell lines. Other direct and indirect indica-
tions that support an important role for autophagy are that highly
active MTOR signaling, consequently low autophagy activity, and
genetic variation in autophagy genes are associated with poor prog-
nosis of NMTC patients and with a decreased ability for iodide
uptake.11,26-29
By comparing LC3 scoring between tumor tissue and adja-
cent normal thyroid tissue, striking differences were observed.
Whereas active autophagy predisposes to high uptake and to
effective clinical responses to RAI therapy, this relationship was
not observed in adjacent normal thyroid tissue surrounding
these tumors. These differences might provide additional
insights into the differential role of autophagy in malignant
cells as opposed to normal thyroid follicular cells; cells that
have been subjected to malignant transformation could deploy
the autophagy pathway to maintain their differentiated state,
whereas in normal thyroid cells the signiﬁcance of autophagy
to sustain thyroid-speciﬁc gene expression remains unapparent,
most probably because the differentiation signature is not
threatened by aberrant signaling evoked by oncogenic
pathways.
In contrast to the profound association of autophagy activity
with the clinical success rate of RAI therapy, no signiﬁcant
associations were observed in the comparison of LC3 scoring
with either normal, benign or malignant thyroid tissues. These
observations suggest that the absence or presence of active
autophagy is not an independent driving force in malignant
transformation of thyroid follicular cells, but might rather rep-
resent an important effect modiﬁer of the clinical course of
NMTC. In line with this, although only 3 ATC patients were
analyzed, all displayed low autophagy expression and activity,
conﬁrming the inverse relationship between autophagy and
NMTC aggressiveness. It remains to be determined whether
the degree of autophagy activity also predisposes to a differen-
tial clinical course of benign thyroid disease, which is beyond
the scope of the current study.
Identiﬁcation of molecular players and biological mecha-
nisms underlying the beneﬁcial effects of autophagy on
maintaining differentiation of NMTC cells requires further
in-depth analysis of autophagy modulation in in vitro stud-
ies on NMTC cell lines and delineation of molecular signa-
tures associated with differential expression and activity of
autophagy in human tumor material. From the present
study it can be deduced that these represent mechanisms
most likely acting upon the regulation of autophagy activity
rather than LC3 protein expression. As an alternative mech-
anism, increased numbers of LC3-II-positive puncta could
also reﬂect impaired autophagosome maturation, which is
indistinguishable from increased autophagic ﬂux in ﬁxated
human tissue specimens. No clear association of LC3-II
with SQSTM1 expression was observed, indicating that
SQSTM1 could predominantly be regulated by other mecha-
nisms, as previously reported.30,31 Another interesting
observation is that most of the autophagosomes detected by
electron microscopy appeared to contain colloid, a natural
component of thyroid follicles located at the apical side of
follicular cells. Future studies are warranted to conﬁrm this
and to explore its signiﬁcance in thyroid carcinogenesis.
In recent years, several anticancer therapies have been
tested for their ability to increase the therapeutic success of
RAI therapy by inducing redifferentiation in NMTC. Of
these, the selective BRAFV600E inhibitor dabrafenib and the
MAP2K/MEK inhibitor selumetinib display beneﬁcial effects
in small cohorts of RAI-refractory NMTC patients, of which
60% exhibit partial responses or stable disease after treat-
ment with either dabrafenib or selumetinib followed by 131I
RAI ablation therapy.32,33 It is well established that cellular
Table 2. Correlation between patient characteristics and category of autophagy activity score in the corresponding NMTC tumor tissues (LC3-II-positive puncta).
Category autophagy activity (LC3-II positive puncta)
Patient characteristics None (N=7) Low (N=20) Intermediate (N=24) High (N=17) Maximum (N=9) P-value
Age at diagnosis in years (mean [§ SD]) 49.7 (§17 .7) 52.4 (§16 .6) 51.0 (§15 .6) 49.9 (§13 .6) 47.6 (§11 .4) 0.915
Gender (Female/Male) 4/3 14/6 17/7 11/6 6/3 0.845
T-stage T1 — 2 (10.0%) 1 (4.2%) — — 0.405
T2 1 (14.3%) 3 (15.0%) 4 (16.7%) 1 (5.9%) —
T3 1 (14.3%) 1 (5.0%) 3 (12.5%) 3 (17.6%) 5 (55.6%)
T4 4 (57.1%) 12 (60.0%) 15 (62.5%) 12 (70.6%) 4 (44.4%)
Tx 1 (14.3%) 2 (10.0%) 1 (4.2%) 1 (5.9%) —
N-stage N0 3 (42.9%) 8 (40.0%) 11 (45.8%) 12 (70.6%) 6 (66.7%) 0.124
N1 4 (57.1%) 9 (45.0%) 7 (29.2%) 5 (29.4%) 2 (22.2%)
Nx 3 (15.0%) 6 (25.0%) — 1 (11.1%)
M-stage M0 6 (85.7%) 16 (80.0%) 13 (54.2%) 10 (58.8%) 7 (77.8%) 0.111
M1 1 (14.3%) 3 (15.0%) 8 (33.3%) 4 (23.5%) 2 (22.2%)
Mx — 1 (5.0%) 3 (12.5%) 3 (17.6%) —
Nr. RAI treatments 0-1 2 (28.6%) 7 (35.0%) 13 (54.2%) 13 (76.5%) 9 (100.0%) 0.014
2 5 (71.4%) 13 (65.0%) 11 (45.8%) 4 (23.5%) —
Cumulative RAI dose <100 mCi 1 (14.3%) 5 (25.0%) 9 (37.5%) 8 (47.1%) 5 (55.6%) 0.026
100-200 mCi 3 (42.9%) 3 (15.0%) 5 (20.8%) 7 (41.2%) 3 (33.3%)
>200 mCi 3 (42.9%) 12 (60.0%) 10 (41.7%) 2 (11.8%) 1 (11.1%)
Disease after ablation Remission 2 (28.6%) 7 (35.0%) 13 (54.2%) 14 (82.4%) 8 (88.9%) 0.031
Persistent 5 (71.4%) 13 (65.0%) 11 (45.8%) 3 (17.6%) 1 (11.1%)
Disease status during follow-up Remission 1 (14.3%) 5 (25.0%) 14 (58.3%) 15 (88.2%) 7 (77.8%) 0.042
Persistent 5 (71.4%) 14 (70.0%) 10 (41.7%) 2 (11.8%) 2 (22.2%)
Recurrent 1 (14.3%) 1 (5.0%) — — —
P-values are generated by comparing group “none C low” with group “intermediateC high C maximum."
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signaling through oncogenic kinases, including BRAF and
MAP2K, intertwine with autophagy pathways.34-37 Based on
these considerations and the important role of autophagy in
promoting a well-differentiated state in NMTC cells as sug-
gested by the present study, one could envision that inhibi-
tors of BRAF and MAP2K kinases lead to concomitant
modulation of autophagy activity, which could thereby rep-
resent a critical factor inﬂuencing their beneﬁcial clinical
effects. Importantly, subsequent analyses are warranted in
order to assess whether the magnitude of the observed clini-
cal response to BRAF and MAP2K inhibitors in the respec-
tive studies is correlated with the degree of autophagy
activity in responding and nonresponding thyroid tumors.
In conclusion, the present ﬁndings have important implica-
tions for understanding RAI therapy resistance in NMTC.
They provide evidence for active autophagy as a predictive
marker for maintained cellular quality control and counter-
acted tumor progression and aggressiveness, as also demon-
strated in other tumor types and cancer models.38-40
Furthermore, it indicates that decreased autophagy activity is
accompanied by loss of thyroid-speciﬁc gene expression and by
diminished expression of SLC5A5 on the basal membrane of
malignant thyroid follicular cells.
Materials and methods
Patients
Retrospectively, 180 histological samples from surgically
removed thyroid lesions representing 7 different histological
thyroid disorders and adjacent normal thyroid tissue were
obtained from the pathological archive of the Leiden University
Medical Center, The Netherlands. Ethical approval was
obtained for all analyzed patient tissue specimens. We ran-
domly selected 100 benign thyroid tissue samples (normal,
N D 64; Graves disease, N D 10; multinodular goiter, N D 14;
and follicular adenoma, all microfollicular, N D 12). In total 80
NMTC tissue samples (papillary TC [PTC], N D 53; follicular
TC [FTC], N D 13; follicular variant of PTC [FVPTC], N D 11;
anaplastic TC [ATC], N D 3) were selected based on their clini-
cal response to RAI therapy in order to include sufﬁcient num-
bers of both responding and nonresponding patients. All
original histological diagnoses were reviewed by 2 independent
observers. Patient data on demographic and clinical character-
istics including tumor histology and TNM stage at diagnosis
and information on tumor treatment and follow-up, i.e. the
number of RAI therapy sessions and cumulative RAI dose were
retrieved from the patient’s medical records. Primary treatment
of NMTC patients consisted of total or near-total thyroidec-
tomy in all of the patients and modiﬁed radical neck dissections
in patients with conﬁrmed nodal metastases. This was followed
by ablation with RAI (131I) of residual thyroid tissue after sur-
gery. If necessary, patients were treated multiple times with
RAI to reach remission. Initial cure was deﬁned as undetectable
thyroid-stimulating hormone-stimulated thyroglobulin (TG) in
the absence of anti-TG antibodies or no evidence of loco-
regional disease or distant metastasis on post therapeutic
whole-body iodine scintigraphies and/or neck ultrasonographic
examinations at 6–12 mo after RAI ablation. Disease status
during follow-up was deﬁned as remission in case of undetect-
able TG in the absence of anti-TG antibodies and no evidence
of loco-regional disease or distant metastases at the last follow-
up visit. Tumor recurrence was deﬁned as new evidence of
loco-regional disease or distant metastasis, also comprising bio-
chemical recurrence based on TG positivity, more than 6 mo
after successful primary therapy. Persistent disease was deﬁned
as detectable TG and/or evidence of loco-regional disease or
distant metastases.
Transmission electron microscopy
Fresh NMTC tissue was cut into small blocks and ﬁxed in 2%
buffered glutaraldehyde for at least 24 h. The tissue blocks were
washed with 0.1M cacodylate buffer and post-ﬁxed in 2% buff-
ered osmium tetroxide for 1 h. The samples were dehydrated in
a sequence of ethanol and propylene oxide, followed by EMbed
812 (Electron Microscopy Sciences, 14120) with propylene until
it was pure EMbed 812 resin. The tissue samples were embedded
in EMbed 812. Ultrathin sections were cut on a Leica Ultracut
and stained with uranyl acetate and lead citrate. Photographs
were taken on a Jeol 1400 electron microscope at 60 kV.
Tissue microarrays
Formalin-ﬁxed, parafﬁn-embedded blocks routinely prepared
from the surgical specimens of thyroid tumors were selected
for this study. Representative areas containing tumor or adja-
cent normal tissues were identiﬁed by a pathologist (HM).
Triplicate tissue cores with a diameter of 0.6 mm were taken
from each specimen (Beecher Instruments, Silver Springs, MD,
USA) and arrayed on a recipient parafﬁn block, using standard
procedures.22,41
LC3 immunoﬂuorescence and SQSTM1
immunohistochemistry
Four-micrometer consecutive tissue sections were cut from each
arrayed parafﬁn block and prepared on pathological slides. The
sections were deparafﬁnized in xylene and rehydrated in 100, 96
and 70% ethanol, successively. Subsequently, nonspeciﬁc binding
sites were blocked by incubation with 20% normal goat or mouse
serum (DAKO, X0907 or X0910, respectively) in phosphate-
buffered saline (PBS; Fresenius Kabi GmbH, M090001). Then
the sections were incubated with the polyclonal rabbit-anti-
human LC3B primary antibody (1:200; Abcam, ab48394) or
SQSTM1 primary antibody (1:400; BD Biosciences, 610832)
diluted in PBSC 1% BSA (Sigma, A9418) overnight at 4C. After
3 washing steps with PBS, LC3-stained sections were incubated
for 1 h with goat-anti-rabbit Alexa Fluor 647 secondary antibody
(ThermoFisher Scientiﬁc, A-21245) diluted 1:100 in PBS C 1%
BSA. Sections were mounted with Vectashield containing diami-
dino-2-phenylindole (Vector Laboratories, H-1200). Negative
controls were stained with the primary antibody omitted. Stain-
ings were observed and scanned by a confocal laser-scanning
microscope with 1000x magniﬁcation (Zeiss LSM700, Oberko-
chen, Germany). SQSTM1 stained sections were incubated with
horseradish peroxidase conjugated secondary antibody (DAKO,
P0161) 1:500 diluted in PBS C 1% BSA. The endogenous
1202 T. S. PLANTINGA ET AL.
peroxidase activity was blocked with 3% H2O2 in methanol for
15 min at room temperature. Furthermore, because tumor-like
tissues contain endogenous biotin, this was blocked in the tissue
sections by an avidin-biotin blocking kit according to the manu-
facturer’s protocol (Vector Laboratories, SP-2001). The ABC–
horseradish peroxidase complex (Vector Laboratories, PK-6101),
1:200 diluted in PBS, was applied to the sections for 30 min at
room temperature. The substrate solution was added for 5 min
at room temperature: 0.5 ml of diaminobenzidene in 9.5 ml of
PBS and 10 ml of H2O2. Tissues were counterstained with hema-
toxylin for 30 sec at room temperature. Slides were dehydrated
with consecutive incubation in 70, 96 and 100% of alcohol and
xylene (2 times) for 5 min each step. Sections were mounted in
Permount (ThermoFisher Scientiﬁc, SP15–500).
LC3-I intensity and LC3-II-positive puncta scoring
A semiquantitative assessment of immunohistochemical
scoring was performed taking into account both the inten-
sity of diffuse LC3-I staining (autophagy expression) and
the number of ﬂuorescent LC3-II-positive puncta (auto-
phagy activity). The diffuse LC3-I staining intensity within
cells was scored as follows: none, ‘0’; 0–30% (low), ‘1’; 30–
70% (intermediate), ‘2’; and 70–100% (high), ‘3’. The num-
ber of ﬂuorescent LC3-II-positive puncta was scored as
none, ‘0’; low, ‘1’; intermediate, ‘2’; high, ‘3’; and maximum,
‘4’. Observers were blinded for clinical information during
assessment of LC3-I and LC3-II staining. Scoring results
were generated in triplicate for all patient tissues. Both
parameters were assessed independently by 2 observers. In
case of scoring discrepancies between triplicates or between
the observers, which occurred in 18% of all specimens, tis-
sue staining was re-evaluated and scoring consensus was
reached. Only after all scoring data were collected, correla-
tions with clinical data were performed.
TPC-1 cell culture and LC3 analysis
The NMTC cell line TPC-1 (papillary, RET/PTC rearrange-
ment) was obtained from the source previously described
and was authenticated by short tandem repeat proﬁling.42
TPC-1 was cultured in DMEM medium (Invitrogen, 10566–
016) supplemented with 10 mg/ml gentamicin, 10 mM L-
glutamine, 10 mM pyruvate, and 10% fetal calf serum
(ThermoFisher Scientiﬁc, 10270). Cells were grown on cover
slips or in 6-well plates (5£106 cells/well) and were incu-
bated with dimethyl sulfoxide vehicle (Millipore, 317275) or
with 3-methyladenine (10 mM, Sigma, M9281) for 4 h. For
immunoﬂuorescent LC3 staining, cells were ﬁxed with 4%
paraformaldehyde and permeabilized by cold methanol. For
the remaining, ﬂuorescent protein staining was performed
according to the same protocol as described above. Quanti-
tative scoring of LC3-I and LC3-II was performed with FIJI
software. For immunoblotting of LC3 and GAPDH, cell
lysates were subjected to protein electrophoresis on a 15%
polyacrylamide gel. Protein transfer was performed on
nitroglycerine membranes using the wet-blotting method
(Bio-Rad, Hercules, CA, USA) and was followed by block-
ing, incubation with ﬁrst (1:500; Abcam, ab48394) and
second (ThermoFisher Scientiﬁc, A-21245) ﬂuorescent anti-
body, each time using 5% (w/v) milk powder in Tris-buff-
ered saline (Agilent Technologies, S3001) containing Tween
20 (Millipore, 655204). Fluorescent signal was detected by
Odyssey equipment (Westburg, Leusden, The Netherlands).
Statistical analysis
Associations of diffuse LC3-I intensity and number of LC3-II-
positive puncta with thyroid pathology, clinical response to
RAI therapy and membranous SLC5A5 expression (data
obtained from previous study, see reference 22) were tested by
2-sided Chi-square tests. Furthermore, the following parame-
ters were analyzed and correlated with autophagy scoring with
the same statistical methods: (I) the tumor size at time of diag-
nosis was classiﬁed according to the sixth edition of the Union
for International Cancer Control TNM classiﬁcation;43 (II) the
number of RAI treatments (including RAI ablation) as 0–1
treatments (e.g., no RAI ablation or exclusively ablation of thy-
roid rests after near-total thyroidectomy) or 2 treatments;
(III) the cumulative RAI dosage as <100 mCi (<3.7 GBq),
101–200 mCi (3.8 – 7.4 GBq) or >200 mCi (>7.4 GBq) and
(IV) the disease status after ablation and during follow-up
expressed as remission, persistent or recurrent. Logistic regres-
sion was performed to generate odds ratios and 95% conﬁdence
intervals. For calculation of these values, comparison of LC3-I
intensity scores was performed based on the formation of 2
scoring groups: (1) score none-low and (2) score intermediate-
high, whereas for LC3-II-positive puncta scores this was gener-
ated by comparing scoring groups (1) score none-low and (2)
score intermediate-high-maximum. Quantitative LC3 scoring
of TPC-1 was statistically analyzed by Mann-Whitney U tests.




ATC anaplastic thyroid carcinoma
ATG autophagy related
BSA bovine serum albumin
FTC follicular thyroid carcinoma
FVPTC follicular variant papillary thyroid carcinoma
LC3 microtubule associated protein 1A/1B light
chain 3
MTOR mechanistic target of rapamycin (serine/threo-
nine kinase)
NMTC non-medullary thyroid cancer
OR odds ratio
PBS phosphate-buffered saline
PTC papillary thyroid carcinoma
RAI radioactive iodine
RET rearranged during transfection
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